UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer

Current treatment options in oncology, 2021-10, Vol.22 (10), p.91-91, Article 91

2021

Volltextzugriff (PDF)

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

PloS one, 2009-12, Vol.4 (12), p.e8199-e8199

2009

Volltextzugriff (PDF)

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database

Thoracic cancer, 2020-11, Vol.11 (11), p.3357-3364

2020

Volltextzugriff (PDF)

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

ESMO open, 2017, Vol.2 (3), p.e000219-e000219, Article e000219

2017

Volltextzugriff (PDF)

Cancer stem cells and cisplatin‐resistant cells isolated from non‐small‐lung cancer cell lines constitute related cell populations

Cancer medicine (Malden, MA), 2014-10, Vol.3 (5), p.1099-1111

2014

Volltextzugriff (PDF)

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11464

2023

Volltextzugriff (PDF)

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350

2018

Volltextzugriff (PDF)

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929

2017

Volltextzugriff (PDF)

ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications

International journal of oncology, 2012-06, Vol.40 (6), p.2104-2110

2012

Volltextzugriff (PDF)

Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer

Biomedicines, 2022-04, Vol.10 (5), p.1047

2022

Volltextzugriff (PDF)

Cancer and acute cardiovascular diseases: team work to transform the clinical practice

European heart journal. Acute cardiovascular care, 2021-10, Vol.10 (8), p.840-842

2021

Volltextzugriff (PDF)

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

Cancer chemotherapy and pharmacology, 2021-04, Vol.87 (4), p.475-486

2021

Volltextzugriff (PDF)

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

Clinical & translational oncology, 2023-11, Vol.25 (11), p.3139-3151

2023

Volltextzugriff (PDF)

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408

2019

Volltextzugriff (PDF)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

ClinicoEconomics and outcomes research, 2012-01, Vol.4 (default), p.269-275

2012

Volltextzugriff (PDF)

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723

2020

Volltextzugriff (PDF)

The impact of next-generation sequencing on the DNA methylation–based translational cancer research

Translational research : the journal of laboratory and clinical medicine, 2016-03, Vol.169, p.1-18.e1

2016

Volltextzugriff (PDF)

Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells

Cancer biology & therapy, 2007-10, Vol.6 (10), p.1600-1605

2007

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

The New England journal of medicine, 2023-07, Vol.389 (2), p.137-147

2023

Volltextzugriff (PDF)

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

Lung cancer (Amsterdam, Netherlands), 2015-05, Vol.88 (2), p.215-222

2015

Volltextzugriff (PDF)

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

British journal of clinical pharmacology, 2018-06, Vol.84 (6), p.1156-1169

2018

Volltextzugriff (PDF)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

British journal of cancer, 2019-07, Vol.121 (2), p.131-138

2019

Volltextzugriff (PDF)

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

Clinical & translational oncology, 2023-11, Vol.25 (11), p.3073-3085

2023

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(101)

Publikationsform

Artikel
(97)
Berichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(57)
Humans
(52)
Oncology
(51)
Male
(31)
Middle Aged
(31)
Female
(30)
Aged
(26)
Lung Cancer
(26)
Lung Neoplasms - Drug Therapy
(22)
Adult
(21)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(20)
Chemotherapy
(19)
Aged, 80 And Over
(16)
Lung Neoplasms - Pathology
(16)
Pulmonary/respiratory
(16)
Tumors
(16)
Carcinoma, Non-Small-Cell Lung - Pathology
(15)
Patients
(15)
Immunotherapy
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Cancer stem cells and cisplatin‐resistant cells isolated from non‐small‐lung cancer cell lines constitute related cell populations

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications

Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Cancer and acute cardiovascular diseases: team work to transform the clinical practice

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The impact of next-generation sequencing on the DNA methylation–based translational cancer research

Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

Suchergebnisse filtern